Literature DB >> 2842408

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents.

B Meignier1, R Longnecker, B Roizman.   

Abstract

The herpes simplex virus (HSV) recombinant R7017 was constructed from HSV-1 (strain F) by deleting a portion of the thymidine kinase (tk) gene and by replacing the sequences representing the internal inverted repeats and adjacent genes in the L component with a fragment of the HSV-2 genome encoding the glycoproteins G, D, I, and a portion of E. In addition, the R7020 recombinant contains an HSV-1 DNA fragment encoding the tk gene fused to the alpha 4 gene promoter. The results of studies in mice, guinea pigs, and rabbits were as follows: Both recombinants remained unchanged after nine serial, intracerebral passages in mice; the recombinants could not be differentiated with respect to attenuation in mice injected intracerebrally, in vaginally infected guinea pigs, and in rabbits inoculated on the scarified cornea. Given intradermally or intramuscularly, the recombinants prevented severe infections by virulent challenge viruses, and R7020 established latent infections (at a low frequency) in all species tested, whereas latent R7017 virus was detected in rabbits only.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842408     DOI: 10.1093/infdis/158.3.602

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  64 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

2.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 3.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 5.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

6.  Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow.

Authors:  Christopher L Skelly; Amito Chandiwal; James E Vosicky; Ralph R Weichselbaum; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

Review 7.  Immune responses to herpesviral vectors.

Authors:  Deborah A Ryan; Howard J Federoff
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

Review 8.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

9.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors:  Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.